Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Noboru Konishi

Motoo Yamasaki

Ken Kobayashi

Shiro Akinaga

Toshiyuki Suzawa

Kumiko Maruyama

Kazuhisa Uchida

Hideharu Anazawa

Tatsuya Tamaoki

Yukimasa Shiotsu

Haruhiko Yokoi

Kinya Yamashita

Yoko Kato

The present invention relates to a chemically modified polypeptide in which at least one of hydroxyl groups in the polypeptide molecule is modified with a polyalkylene glycol derivative; a method for producing the modified polypeptide; a method of treatment using the modified polypeptide; use of the modified polypeptide; a pharmaceutical preparation comprising the modified polypeptide; and a composition for treatment comprising the modified polypeptide.

Chemically modified polypeptides

The present invention relates to a fusion polypeptide which comprises a polypeptide having G-CSF activity and a polypeptide having TPO activity and DNA which codes for the fusion polypeptide, to a fusion polypeptide in which a polypeptide having G-CSF activity and a polypeptide having TPO activity are fused via a spacer peptide and DNA which codes for the fusion polypeptide and to a polypeptide in which the fusion polypeptide comprising a polypeptide having G-CSF activity and a polypeptide having TPO activity is chemically modified with a polyalkylene glycol derivative. It also relates to an anemia-treating composition containing the fusion polypeptide as an active ingredient.

hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same

Growing community of inventors

Hofu, Japan

Noboru Konishi